Under the agreement, Iktos will apply its de novo ligand and structure-based generative modeling technologies, its AI-based retrosynthesis analysis and planning tool Spaya™, and know-how complementing DDU’s drug discovery capabilities to expedite the identification of potential pre-clinical candidates and to identify additional novel chemical matter with suitable properties. Follow the link for the full press release.
